NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Valneva and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 23, 2026, Va ...

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts The transcript and webcast replay of the call will be made available on our web site at www.pfizer.com/investorswithin 24 hours after the end of the live conference call and will be accessible for at least 90 days. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bri ...

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial Mar 23, 2026 6:45 AM Eastern Daylight Time Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial Share NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR "Vaccine Against Lyme for Outdoor Recreationists†clinical trial (NCT0 ...